Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
TherapeuticsMD, Inc. entered into Subscription Agreement with Rubric Capital Management LP valued at $7 million (effective 2022-10-28).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- Rubric Capital Management LP
- Value
- $7 million
- Effective
- 2022-10-28
Exact text from the filing
On October 28, 2022, TherapeuticsMD, Inc., a Nevada corporation (the “Company”), entered into a Subscription Agreement (the “Subscription Agreement”) with Rubric Capital Management LP (the “Investor”), pursuant to which the Company issued and sold, in a private placement offering (the “Offering”), 7,000 shares of the Company’s Series A Preferred Stock, par value $0.001 per share (the “Series A Preferred Stock”), for an aggregate offering price of $7 million.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 1.0
TherapeuticsMD, Inc. entered into Lender Subscription Agreement with the Lenders (effective 2022-10-28).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- the Lenders
- Effective
- 2022-10-28
Exact text from the filing
on October 28, 2022 the Company issued warrants (the “Lender Warrants”), to the Lenders to purchase an aggregate of 125,000 shares of Common Stock, pursuant to a subscription agreement by and among the Company and the Lenders (the “Lender Subscription Agreement”), and the maturity date of the Financing Agreement was extended to November 30, 2022.
View on SEC.gov